CVS Health Corporation $CVS Shares Purchased by KCM Investment Advisors LLC

KCM Investment Advisors LLC boosted its position in shares of CVS Health Corporation (NYSE:CVS) by 30.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 28,061 shares of the pharmacy operator’s stock after purchasing an additional 6,491 shares during the quarter. KCM Investment Advisors LLC’s holdings in CVS Health were worth $2,015,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Norges Bank acquired a new position in shares of CVS Health during the 4th quarter worth $1,666,265,000. Wellington Management Group LLP grew its stake in CVS Health by 193.2% in the 4th quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock valued at $1,473,270,000 after acquiring an additional 12,233,675 shares during the last quarter. Amundi increased its holdings in CVS Health by 95.3% during the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after acquiring an additional 3,637,943 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in CVS Health by 44.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,219,756 shares of the pharmacy operator’s stock worth $446,703,000 after acquiring an additional 1,899,932 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of CVS Health by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock valued at $9,579,508,000 after purchasing an additional 1,824,424 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CVS. JPMorgan Chase & Co. raised their price objective on shares of CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Mizuho increased their target price on CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Monday, June 8th. Weiss Ratings raised CVS Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, July 20th. Morgan Stanley boosted their price target on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. Finally, Sanford C. Bernstein upped their price objective on CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a research report on Tuesday, May 12th. Twenty-one equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $105.67.

CVS Health Trading Up 2.2%

CVS stock opened at $109.41 on Wednesday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The company has a market cap of $139.59 billion, a price-to-earnings ratio of 48.20, a PEG ratio of 1.05 and a beta of 0.61. The business has a fifty day simple moving average of $100.73 and a 200-day simple moving average of $86.56. CVS Health Corporation has a 52 week low of $58.99 and a 52 week high of $110.68.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter last year, the firm earned $2.25 earnings per share. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities research analysts expect that CVS Health Corporation will post 7.46 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, July 23rd. CVS Health’s dividend payout ratio is 117.18%.

Insider Activity at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares in the company, valued at $586,842,501.45. The trade was a 24.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,441,551 shares of company stock worth $323,703,977 in the last 90 days. 0.85% of the stock is currently owned by insiders.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS has recently outperformed the broader market, reflecting strong investor momentum following its earnings beat and improving outlook. CVS Health Laps the Stock Market
• Positive Sentiment: Analyst coverage remains broadly constructive, with CVS included among healthcare companies showing favorable indicators ahead of second-quarter 2026 results. Expectations for an earnings beat could support the stock, although execution and margins remain important. Zacks Analyst Blog Highlights CVS Health
• Positive Sentiment: CVS is again identified as one of four medical stocks positioned for a potential second-quarter earnings beat, supported by resilient demand for healthcare products and services. Medical Stocks With the Right Setup for Earnings Beats
• Positive Sentiment: Kate Farms is expanding distribution of its high-protein nutrition shakes into CVS stores, adding another health and wellness product that could modestly increase customer traffic and product breadth. Kate Farms Expands Distribution Into CVS
• Neutral Sentiment: Humana’s upcoming results are drawing attention to Medicare Advantage medical costs and guidance. A favorable report could reinforce sentiment toward health insurers, while cost pressure could have the opposite effect for CVS. Humana Earnings Face High Expectations
• Neutral Sentiment: CVS also highlighted community investments in Massachusetts, caregiving initiatives and recognition for supply-chain work. These support the company’s reputation but are unlikely to materially change near-term earnings. CVS Health Helping Strengthen Communities

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.